NCT03719560WithdrawnPhase 2

Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma

Source: ClinicalTrials.gov · Last updated 13 Apr 2020

Reason given: lack of funding

Brief summary (registry, in English)

Phase 2 single-institution trial of early systemic central nervous system prophylaxis in high-risk diffuse large B-cell lymphoma

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

New diagnosis of diffuse large B-cell lymphoma, planned first-line therapy using the standard rituximab- and anthracycline-containing regimens
No central nervous system involvement on initial staging
Performance status of 0 or 1 (Eastern Cooperative Oncology Group scale)
Renal function: creatinine clearance >45 ml/min
Not pregnant; agreeable to contraception
Written informed consent
High risk for central nervous system recurrence as determined by one of the following high-risk features:
- high central nervous system International Prognostic Index,
- testicular, breast, or uterine involvement,
- dual expresser or double/triple-hit status,
- HIV positive status, or
- Molecularly defined high-risk subtype.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Sites in registry order. Save your city in your profile to sort them by distance.

Site	City	Country	Site status
Roxanne Wood	Providence	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.